Anthem Biosciences Ltd. IPO

We are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (“NCE”) and New ... Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. We provide end to end CRDMO services and we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Our CRDMO platform comprises 5 main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and 4 manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). We derive revenue primarily from our CRDMO services, including developmental and commercial manufacturing, and research and development services. We also generate revenue from the manufacture and sale of specialty ingredients. Read more

According to the F&S Report, the global pharmaceutical industry is projected to grow to U.S.$ 2,076.0 billion by 2029, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models. According to the F&S Report, the Indian CRDMO industry is ... expected to grow at a CAGR of 13.4% from 2024 to 2029 to reach an estimated value of U.S.$ 15.4 billion, which outpaces the global industry rate of 9.1% and other markets, although pharma companies are subject to challenges such as cost pressures, low rate of experimental compounds moving to commercialization stage and increased regulatory oversight. Read more